Skip to main content

Ixchiq Disease Interactions

There is 1 disease interaction with Ixchiq (chikungunya vaccine, live (cvx 317)).

Moderate

Vaccines (live attenuated/toxoid) (applies to Ixchiq) immunocompromised

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency

The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy. Caution and close monitoring is advised.

References

  1. (2005) "Product Information. Menactra (meningococcal conjugate vaccine)." sanofi pasteur
  2. (2022) "Product Information. ActHIB (Hib) (haemophilus b conjugate (PRP-T) vaccine)." sanofi pasteur
  3. (2022) "Product Information. Bexsero (meningococcal group B vaccine)." Novartis Vaccines & Diagnostics Inc
  4. (2022) "Product Information. Trumenba (meningococcal group B vaccine)." Pfizer U.S. Pharmaceuticals Group
  5. (2022) "Product Information. Hiberix (Hib) (haemophilus b conjugate (PRP-T) vaccine)." GlaxoSmithKline
  6. (2016) "Product Information. Vaxchora (cholera vaccine, live)." PaxVax
  7. (2022) "Product Information. Vaxchora (cholera vaccine, live)." Emergent Travel Health, Inc
  8. (2023) "Product Information. Ixchiq (cvx 317) (chikungunya vaccine, live (cvx 317))." Valneva USA
View all 8 references

Ixchiq drug interactions

There are 315 drug interactions with Ixchiq (chikungunya vaccine, live (cvx 317)).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.